Breaking Finance News

Zacks Investment Research downgraded EnteroMedics Inc (NASDAQ:ETRM) to Hold in a report released today.

Yesterday EnteroMedics Inc (NASDAQ:ETRM) traded -6.61% lower at $0.13. The company’s 50-day moving average is $0.15 and its 200-day moving average is $0.44. The last stock close price is down -72.56% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 3,695,230 shares of the stock were exchanged, down from an average trading volume of 7,212,220

Zacks Investment Research has downgraded EnteroMedics Inc (NASDAQ:ETRM) to Hold in a report released on Wednesday October 05, 2016.

Previously on Thursday June 09, 2016, Roth Capital reported about EnteroMedics Inc (NASDAQ:ETRM) lowered the target price from $3.00 to $0.50. At the time, this indicated a possible upside of 0.11%.

See Chart Below

EnteroMedics Inc (NASDAQ:ETRM)

EnteroMedics Inc has a 52 week low of $0.11 and a 52 week high of $4.95 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 2 firms have reported on the stock. The consensus target price is $3.75 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About EnteroMedics Inc (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *